Navigation Links
Inflection Biosciences licenses preclinical oncology programs from the CNIO
Date:6/4/2013

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

The compounds leverage the CNIO's considerable expertise in drug discovery and comprise a novel pan-PIM kinase inhibitor program and a number of unique multi-targeting kinase inhibitors combining activity on PIM kinase and additional kinases including the phosphoinositide-3 kinase and the mammalian target of rapamycin (PI3K/mTOR) pathway. All molecules have shown good activity in preclinical models, are orally- available with excellent pharmaceutical properties.

Dr María Blasco, Director of CNIO added "It is a great satisfaction for the CNIO to join forces with the experienced team at Inflection Biosciences, allowing us to take full advantage of our ability to innovate cancer treatments."

Dr Michael O'Neill, Co-Founder and Director of Research and Development at Inflection Biosciences commented "Following an extensive global search we are delighted to have secured assets in late preclinical stages of development of this quality and potential and from an organisation recognised internationally for the quality of its cancer research and its drug discovery programs."


'/>"/>

Contact: Press Office
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
3. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Preclinical studies use specialized ultrasound to detect presence of cancer
8. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
9. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
10. ESMO 2012 Congress: A path for medical oncology innovations
11. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2020)... Calif. (PRWEB) , ... July 01, 2020 , ... ... company, presented its phase 1a findings of Neihulizumab, a biologic for the treatment ... in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, a registered ... common and aggressive adult brain cancer—announced today the appointments of its first Senior ... with supporting the organization’s initiatives and overall vision. , "Senior Fellows are more ...
(Date:6/25/2020)... Mass. (PRWEB) , ... June 24, 2020 , ... ... of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, ... for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, the leader ... tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes at a time ... track capacity to provide patients with urgently needed vaccines and other lifesaving pharmaceutical ...
(Date:7/31/2020)... ... 29, 2020 , ... The SDX® Respiratory Gating System ... has reached its 20th anniversary of worldwide use. Introduced in the US over ... including University of Pennsylvania, University of Michigan, University of Maryland, University of California ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... ... solutions to aid in the early detection and prevention of high-burden diseases, and ... enable US-based hospitals and healthcare organizations to utilize existing data in order to ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., ... hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of ...
Breaking Biology Technology: